Gene Expression and Molecular Cloning Products & Reviews

Modulation of gene expression with modified oligos

CRISPR off-target effect may result in anomalous insertions, deletions and translocation. It is critical to have a sensitive detection tool for the off-target editing. Based on the highly sensitive, accurate and stable TargetSeq® hybridization capture sequencing technology and MultipSeq® multiplex amplicon sequencing technology, iGeneTech provides a new, fast and cost-effective solution for CRISPR off-target validation to dete…

Type VI-S, lyophilized powder, for diagnostic assay manufacturing

Type I-S, 65-85% protein (≥75% of protein is clottable)

1,6-α-D-Glucan 6-glucanohydrolase

Recombinant, expressed in Pichia pastoris, ATPase ≥1000 units/mg protein, lyophilized powder.

Fast-track your route to a modernized workflow with the only in vitro bioavailability assessment tool on the market

Creative Biolabs delivers an end-to-end CAR-T development pathway—from target/scFv discovery, CAR design and vectoring, and cell engineering to in-vitro/in-vivo efficacy, IND authoring, and manufacturing support. Modular and GMP-aligned, the platform spans autologous and allogeneic routes (incl. TRAC/Cas9 and mRNA) to de-risk translation for hematologic and solid tumor programs.

End‑to‑end TCR‑like antibody services targeting peptide–MHC complexes—covering immunogen design, pMHC screening, affinity maturation, developability optimization, and functional validation—with output as IgG, bispecifics, or CAR constructs to access intracellular‑derived antigens.

End‑to‑end solid‑tumor CAR‑T development—from antigen/scFv discovery and CAR optimization to cell engineering, in‑vitro/in‑vivo efficacy, and IND support. Incorporates dual/logic‑gated and armored CARs, plus trafficking and persistence enhancements to overcome the tumor microenvironment and improve safety and translation.

End‑to‑end allogeneic cell therapy development—covering donor strategy, multiplex genome editing for safety/immune evasion, scalable manufacturing and comparability, and IND/CMC support—across CAR‑T/CAR‑NK and other donor‑derived modalities to enable off‑the‑shelf access.

Configurable TIL therapy development spanning tumor processing, TIL isolation/rapid expansion, functional and phenotypic qualification, and release criteria—paired with manufacturing‑aligned process development and IND documentation to de‑risk scale‑up for solid‑tumor programs.

Active, stabilized G-Protein Coupled Receptors (GPCRs), prepared in native-like conformations, for high-throughput screening, ligand binding studies, and structure-based drug discovery.

Unleash the full power of a well-designed library. With Twist Bioscience, you are assured that the library you design contains the specific modifications, exactly where you want them, saving you valuable resources for the downstream screening process.

The CD73 activity assay for HTS and hit-to-lead. Measure specific activity of CD73 in a simple mix-and-read format. The kit is designed for compound library screening and follow-up inhibitor discovery.

Specially formulated for high yields of canonical (GAUC) in vitro transcribed RNA. Produce up to 90 µg of RNA from 1 µg of template in 2 hours. Easily scale up reactions to produce milligram amounts of RNA.

Generate canonical (GAUC) mRNA with greatly reduced double-stranded RNA (dsRNA) content. Easily remove dsRNA without the need for chromatographic methods like HPLC. Produce large amounts of mRNA with virtually 100% transcript capping. Reduce the innate immunogenic response to mRNA in cells.

Amplify micrograms of circular DNA from as little as 5 pg of input. Directly amplify from purified plasmid, glycerol stocks, liquid media cultures, or colonies on agar plates. Accurate amplification, with an error rate of ~1 in 106-107 bases.

Build Cap 0 caps with nearly 100% efficiency. Use simultaneously with ScriptCap™ 2'-O-Methyltransferase to produce Cap 1 caps.

Co-transcriptionally cap in vitro transcribed RNA with Anti-Reverse cap analog (ARCA). Produce up to 60 µg of capped RNA from 1 µg of template in just 30 minutes. Optimized for maximum transcript capping and yield.

All-in-one kit combining the benefits of high-yield transcription with post-transcriptional capping and tailing. Produce large amounts of mRNA with virtually 100% transcript capping.

Specially formulated for high yields of canonical (GAUC) in vitro transcribed RNA. Produce up to 150 µg of RNA from 1 µg of template in 2 hours. Easily scale up reactions to produce milligram amounts of RNA.

Generate N1-methyl-pseudouridine-containing mRNA (N1meΨ-mRNA) with greatly reduced double-stranded RNA (dsRNA) content. Easily remove dsRNA without the need for chromatographic methods like HPLC. Produce large amounts of N1meΨ-mRNA with virtually 100% transcript capping. Induce lower innate immune response in mammalian cells.

Achieve ultra-high RNA yields with MEGAscript™ kits—ideal for in vitro or in vivo translation studies needing unlabeled or low specific activity RNA.